Drivers of poor medical care

The Lancet

Volumn 390, Issue 10090, 2017, Pages 178-190

  Saini, Vikas ^a   Garcia Armesto, Sandra ^b,c   Klemperer, David ^d   Paris, Valerie ^e   Elshaug, Adam G ^a,f   Brownlee, Shannon ^a,g   Ioannidis, John P A ⁱ   Fisher, Elliott S ^h,j  

^a Lown Cardiovascular Group   (United States)

^b FUNDACIÓN ARAID   (Spain)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^d UNIVERSITY OF APPLIED SCIENCES REGENSBURG   (Germany)

^e OECD   (France)

^f UNIVERSITY OF SYDNEY   (Australia)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j DARTMOUTH MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; DOCTOR PATIENT RELATION; DRUG INDUSTRY; EVIDENCE BASED PRACTICE; GLOBAL DISEASE BURDEN; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEURISTICS; HOSPITAL ADMISSION; HOSPITAL FINANCE; HUMAN; HUMAN RELATION; INTENSIVE CARE UNIT; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL FEE; MEDICAL SPECIALIST; MEDICALLY UNINSURED; MONEY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SHARED DECISION MAKING; ATTITUDE TO HEALTH; BIOLOGICAL MODEL; ECONOMICS; HEALTH BEHAVIOR; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HEALTH PERSONNEL ATTITUDE; STANDARDS;

ATTITUDE OF HEALTH PERSONNEL; DELIVERY OF HEALTH CARE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTHCARE FINANCING; HUMANS; MODELS, BIOLOGICAL; PHYSICIAN-PATIENT RELATIONS; QUALITY OF HEALTH CARE;

EID: 85030456506     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30947-3     Document Type: Review

References (214)

1. Lohr, KN, Medicare: a strategy for quality assurance, 1990, National Academies Press, Washington, DC.
2. Crosson, F, Change the microenvironment: delivery system reform essential to controlling costs. http://www.commonwealthfund.org/publications/commentaries/2009/apr/change-the-microenvironment, 2009 (accessed Dec 1, 2016).
3. Meier, DE, Back, AL, Morrison, RS, The inner life of physicians and care of the seriously ill. JAMA 286 (2001), 3007–3014.
4. Keyhani, S, Falk, R, Howell, EA, Bishop, T, Korenstein, D, Overuse and systems of care: a systematic review. Med Care 51 (2013), 503–508.
5. Bernal-Delgado, E, Christiansen, T, Bloor, K, et al., for the ECHO Consortium. ECHO: health care performance assessment in several European health systems. Eur J Public Health 25:suppl 1 (2015), 3–7.
6. OECD. Geographic variations in health care: what do we know and what can be done to Improve health system performance?, 2014, OECD Publishing, Paris.
7. Chassin, MR, Galvin, RW, The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA 280 (1998), 1000–1005.
8. Basu, S, Andrews, J, Kishore, S, Panjabi, R, Stuckler, D, Comparative performance of private and public healthcare systems in low-and middle-income countries: a systematic review. PLoS Med, 9, 2012, e1001244.
9. Remler, DK, Greene, J, Cost-sharing: a blunt instrument. Annu Rev Public Health 30 (2009), 293–311.
10. Reed, M, Fung, V, Price, M, et al. High-deductible health insurance plans: efforts to sharpen a blunt instrument. Health Aff 28 (2009), 1145–1154.
11. Hacker, JS, Market-driven health care: who wins, who loses in the transformation of America's largest service industry. J Health Polit Policy Law 22 (1997), 1443–1448.
12. Böhm, K, Schmid, A, Götze, R, Landwehr, C, Rothgang, H, Five types of OECD healthcare systems: empirical results of a deductive classification. Health Policy 113 (2013), 258–269.
13. Ikegami, N, Yoo, BK, Hashimoto, H, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet 378 (2011), 1106–1115.
14. Penno, E, Gauld, R, Audas, R, How are population-based funding formulae for healthcare composed? A comparative analysis of seven models. BMC Health Serv Res, 13, 2013, 470.
15. Ono, T, Schoenstein, M, Buchan, J, Geographic imbalances in doctor supply and policy responses, 2014, OECD Publishing http://dx.doi.org/10.1787/5jz5sq5ls1wl-en, 2014 (accessed Dec 1, 2016).
16. Léonard, C, Stordeur, S, Roberfroid, D, Association between physician density and health care consumption: a systematic review of the evidence. Health Policy 91 (2009), 121–134.
17. McGuire, TG, Physician agency. Culyer, AJ, Newhouse, JP, (eds.) Handbook of health economics, 2000, Elsevier, Amsterdam, 461–536.
18. Robert, R, Coudroy, R, Ragot, S, et al. Influence of ICU-bed availability on ICU admission decisions. Ann Intensive Care, 5, 2015, 55.
19. Bindman, AB, Grumbach, K, Osmond, D, et al. Preventable hospitalizations and access to health care. JAMA 274 (1995), 305–311.
20. Gibson, OR, Segal, L, McDermott, RA, A systematic review of evidence on the association between hospitalisation for chronic disease related ambulatory care sensitive conditions and primary health care resourcing. BMC Health Serv Res, 13, 2013, 336.
21. Hsiao, WC, The Chinese health care system: lessons for other nations. Soc Sci Med 41 (1995), 1047–1055.
22. Wennberg, D, Dickens, J Jr., Soule, D, et al. The relationship between the supply of cardiac catheterization laboratories, cardiologists and the use of invasive cardiac procedures in northern New England. J Health Services Res Policy 2 (1997), 75–80.
23. Trankle, SA, Is a good death possible in Australian critical and acute settings?: physician experiences with end-of-life care. BMC Palliat Care, 13, 2014, 41.
24. Nolte, E, Pitchforth, E, What is the evidence on the economic impacts of integrated care?. http://www.euro.who.int/__data/assets/pdf_file/0019/251434/What-is-the-evidence-on-the-economic-impacts-of-integrated-care.pdf, 2014 (accessed Dec 1, 2016).
25. Bynum, JP, Andrews, A, Sharp, S, McCollough, D, Wennberg, JE, Fewer hospitalizations result when primary care is highly integrated into a continuing care retirement community. Health Aff 30 (2011), 975–984.
26. Vahidi, RG, Mojahed, F, Jafarabadi, MA, Gholipour, K, Rasi, V, A systematic review of the effect of payment mechanisms on family physician service provision and referral rate behavior. Journal of Pakistan Medical Students 3 (2013), 54–60.
27. Cutler, DM, Zeckhauser, RJ, The anatomy of health insurance. Culyer, AJ, Newhouse, J, (eds.) Handbook of health economics, 2000, Elsevier, Amsterdam, 563–643.
28. Peckham, S, Gousia, K, GP payment schemes review. https://www.kent.ac.uk/chss/docs/GP-payment-schemes-review-Final.pdf, 2014 (accessed Dec 1, 2016).
29. Chandra, A, Cutler, D, Song, Z, Who ordered that? The economics of treatment choices in medical care. Pauly, MV, McGuire, TG, Barros, PP, (eds.) Handbook of health economics, 2012, Elsevier, Amsterdam, 397–432.
30. Cashin, C, Chi, Y-L, Smith, PC, Borowitz, M, Thomson, S, Paying for performance in health care: implications for health system performance and accountability, 2014, McGraw-Hill Education http://www.euro.who.int/__data/assets/pdf_file/0020/271073/Paying-for-Performance-in-Health-Care.pdf (accessed Dec 1, 2016).
31. Glasziou, PP, Buchan, H, Del Mar, C, et al. When financial incentives do more good than harm: a checklist. BMJ, 345, 2012, e5047.
32. Sherry, TB, A note on the comparative statics of pay-for-performance in health care. Health Econ 25 (2015), 637–644.
33. Swedlow, A, Johnson, G, Smithline, N, Milstein, A, Increased costs and rates of use in the California workers' compensation system as a result of self-referral by physicians. N Engl J Med 327 (1992), 1502–1506.
34. Mitchell, JM, Sass, TR, Physician ownership of ancillary services: indirect demand inducement or quality assurance?. J Health Econ 14 (1995), 263–289.
35. Chen, GJ, Feldman, SR, Economic aspect of health care systems: advantage and disadvantage incentives in different systems. Dermatol Clin 18 (2000), 211–214.
36. Street, A, O'Reilly, J, Ward, P, et al. DRG-based hospital payment and efficiency: theory, evidence, and challenges. Busse, R, Geissler, A, Quentin, W, Wiley, M, (eds.) Diagnosis-related groups in Europe: moving towards transparency, efficiency and quality in hospitals, 2011, Open University Press, Maidenhead, 93–114.
37. Siciliani, L, Hurst, J, Tackling excessive waiting times for elective surgery: a comparative analysis of policies in 12 OECD countries. Health Policy 72 (2005), 201–215.
38. Or, Z, Implementation of DRG payment in France: issues and recent developments. Health Policy 117 (2014), 146–150.
39. Pericás, JM, Aibar, J, Soler, N, López-Soto, A, Sanclemente-Ansó, C, Bosch, X, Should alternatives to conventional hospitalisation be promoted in an era of financial constraint?. Eur J Clin Invest 43 (2013), 602–615.
40. Saltman, RB, Busse, R, Mossialos, E, Regulating entrepreneurial behaviour in European health care systems, 2002, Open University Press http://www.euro.who.int/__data/assets/pdf_file/0006/98430/E74487.pdf (accessed Dec 1, 2016).
41. Freeman, HE, Corey, CR, Insurance status and access to health services among poor persons. Health Serv Res, 28, 1993, 531.
42. Selby, JV, Fireman, BH, Swain, BE, Effect of a copayment on use of the emergency department in a health maintenance organization. N Engl J Med 334 (1996), 635–642.
43. Chernew, ME, Newhouse, JP, What does the RAND Health Insurance Experiment tell us about the impact of patient cost sharing on health outcomes?. Am J Manag Care, 14, 2008, 412.
44. Gibson, TB, Ozminkowski, RJ, Goetzel, RZ, The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 11 (2005), 730–740.
45. Liebman, J, Zeckhauser, R, Simple humans, complex insurance, subtle subsidies, 2008, National Bureau of Economic Research http://www.ksg.harvard.edu/jeffreyliebman/simplehumans_wp14330.pdf (accessed Dec 1, 2016).
46. Tefferi, A, Kantarjian, H, Rajkumar, SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc 90 (2015), 996–1000.
47. No authors listed. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients. Prescrire Int 22 (2013), 105–107.
48. Godman, B, Malmstrom, RE, Diogene, E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Rev Clin Pharmacol 8 (2015), 77–94.
49. Goldstein, DA, Chen, Q, Ayer, T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol 1 (2015), 1293–1300.
50. Stevens, P, Diseases of poverty and the 10/90 Gap. http://who.int/intellectualproperty/submissions/InternationalPolicyNetwork.pdf, 2004 (accessed Dec 1, 2016).
51. Makinen, M, Waters, H, Rauch, M, et al. Inequalities in health care use and expenditures: empirical data from eight developing countries and countries in transition. Bull World Health Org Suppl 78 (2000), 55–65.
52. von Philipsborn, P, Steinbeis, F, Bender, ME, Regmi, S, Tinnemann, P, Poverty-related and neglected diseases—an economic and epidemiological analysis of poverty relatedness and neglect in research and development. Glob Health Action, 8, 2015, 25818.
53. McBride, TD, Why are health care expenditures increasing and is there a rural differential?, 2005, RUPRI Center for Rural Health Policy Analysis http://web1.ctaa.org/webmodules/webarticles/articlefiles/ruralpolicybrief.pdf (accessed Dec 1, 2016).
54. Stamatakis, E, Weiler, R, Ioannidis, J, Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest 43 (2013), 469–475.
55. Emdin, CA, Odutayo, A, Hsiao, AJ, et al. Association between randomised trial evidence and global burden of disease: cross sectional study (Epidemiological Study of Randomized Trials—ESORT). BMJ, 350, 2015, h117.
56. Berndt, ER, The US pharmaceutical industry: why major growth in times of cost containment?. Health Aff 20 (2001), 100–114.
57. Sell, SK, Private power, public law: the globalization of intellectual property rights, 2003, Cambridge University Press http://assets.cambridge.org/97805218/19145/sample/9780521819145ws.pdf (accessed Dec 1, 2016).
58. McNeil, BJ, Hidden barriers to improvement in the quality of care. N Engl J Med 345 (2001), 1612–1620.
59. Choudhry, NK, Fischer, MA, Avorn, J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 171 (2011), 814–822.
60. Fisher, ES, Bynum, JP, Skinner, JS, Slowing the growth of health care costs—lessons from regional variation. N Engl J Med 360 (2009), 849–852.
61. Okunade, AA, Murthy, VN, Technology as a ‘major driver’ of health care costs: a cointegration analysis of the Newhouse conjecture. J Health Econ 21 (2002), 147–159.
62. Campillo-Artero, C, Armesto, SG, The merry-go-round of new drugs' appraisal, pricing, and reimbursement (Part 1). http://www.hspm.org/countries/spain25062012/countrypage.aspx#, 2014 (accessed Dec 12, 2016).
63. Bach, PB, Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360 (2009), 626–633.
64. Kessler, DA, Hass, AE, Feiden, KL, Lumpkin, M, Temple, R, Approval of new drugs in the United States: comparison with the United Kingdom, Germany, and Japan. JAMA 276 (1996), 1826–1831.
65. Curfman, GD, Redberg, RF, Medical devices—balancing regulation and innovation. N Engl J Med 365 (2011), 975–977.
66. Sorenson, C, Drummond, M, Improving medical device regulation: the United States and Europe in perspective. Milbank Q 92 (2014), 114–150.
67. Redberg, RF, Sham controls in medical device trials. N Engl J Med 371 (2014), 892–893.
68. Moseley, D, Elliott, J, Gregson, M, Higgins, S, Miller, J, Newton, D, Frameworks for thinking: a handbook for teaching and learning, 2005, Cambridge University Press, Cambridge.
69. Chimowitz, MI, Lynn, MJ, Derdeyn, CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365 (2011), 993–1003.
70. Wingspan™ Stent System with Gateway™ PTA Balloon Catheter-H50001: US Food and Drug Administration.
71. Smith, D, Loewenstein, G, Jepson, C, Jankovich, A, Feldman, H, Ubel, P, Mispredicting and misremembering: patients with renal failure overestimate improvements in quality of life after a kidney transplant. Health Psychol, 27, 2008, 653.
72. Kureshi, F, Jones, PG, Buchanan, DM, Abdallah, MS, Spertus, JA, Variation in patients' perceptions of elective percutaneous coronary intervention in stable coronary artery disease: cross sectional study. BMJ, 349, 2014, g5309.
73. Engel, GL, The need for a new medical model: a challenge for biomedicine. Science 196 (1977), 129–136.
74. Macleod, MR, Michie, S, Roberts, I, et al. Biomedical research: increasing value, reducing waste. Lancet 383 (2014), 101–104.
75. Bekelman, JE, Li, Y, Gross, CP, Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289 (2003), 454–465.
76. Ioannidis, JP, Stealth research: is biomedical innovation happening outside the peer-reviewed literature?. JAMA 313 (2015), 663–664.
77. Ioannidis, JP, Prasad, V, Evaluating health system processes with randomized controlled trials. JAMA Intern Med 173 (2013), 1279–1280.
78. Deber, RB, Kraetschmer, N, Irvine, J, What role do patients wish to play in treatment decision making?. Arch Intern Med 156 (1996), 1414–1420.
79. Tversky, A, Kahneman, D, Judgment under uncertainty: heuristics and biases. Science 185 (1974), 1124–1131.
80. Hall, MA, Zheng, B, Dugan, E, et al. Measuring patients' trust in their primary care providers. Med Care Res Rev 59 (2002), 293–318.
81. Sofaer, S, Firminger, K, Patient perceptions of the quality of health services. Annu Rev Public Health 26 (2005), 513–559.
82. Towle, A, Godolphin, W, Framework for teaching and learning informed shared decision making. BMJ 319 (1999), 766–771.
83. Charles, C, Gafni, A, Whelan, T, Self-reported use of shared decision-making among breast cancer specialists and perceived barriers and facilitators to implementing this approach. Health Expect 7 (2004), 338–348.
84. Moyer, VA, What we don't know can hurt our patients: physician innumeracy and overuse of screening tests. Ann Intern Med 156 (2012), 392–393.
85. d'Agincourt-Canning, L, Experiences of genetic risk: disclosure and the gendering of responsibility. Bioethics 15 (2001), 231–247.
86. Blumenthal-Barby, JS, Krieger, H, Cognitive biases and heuristics in medical decision making: a critical review using a systematic search strategy. Med Decis Making 35 (2015), 539–557.
87. Forrow, L, Taylor, WC, Arnold, RM, Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 92 (1992), 121–124.
88. Barbash, GI, Glied, SA, New technology and health care costs—the case of robot-assisted surgery. N Engl J Med 363 (2010), 701–704.
89. Alkhateeb, S, Lawrentschuk, N, Consumerism and its impact on robotic-assisted radical prostatectomy. BJU Int 108 (2011), 1874–1878.
90. Schwartz, LM, Woloshin, S, Fowler, FJ Jr, Welch, HG, Enthusiasm for cancer screening in the United States. JAMA 291 (2004), 71–78.
91. Weeks, JC, Catalano, PJ, Cronin, A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med, 367, 2012, 10.
92. Prus, N, Grant, AC, Patient beliefs about epilepsy and brain surgery in a multicultural urban population. Epilepsy Behav 17 (2010), 46–49.
93. Cabana, MD, Rand, CS, Powe, NR, et al. Why don't physicians follow clinical practice guidelines?: a framework for improvement. JAMA 282 (1999), 1458–1465.
94. Sirovich, BE, Lipner, RS, Johnston, M, Holmboe, ES, The association between residency training and internists' ability to practice conservatively. JAMA Intern Med 174 (2014), 1640–1648.
95. Cialdini, RB, Influence, 1987, Harper Collins Publishers, New York.
96. Gilovich, T, Griffin, D, Kahneman, D, Heuristics and biases: the psychology of intuitive judgment, 2002, Cambridge University Press, New York.
97. Kassirer, JP, Wong, JB, Kopelman, RI, Learning clinical reasoning, 1991, Williams & Wilkins, Baltimore.
98. Gigerenzer, G, Gaissmaier, W, Heuristic decision making. Annu Rev Psychol 62 (2011), 451–482.
99. Dawson, NV, Arkes, HR, Systematic errors in medical decision making. J Gen Intern Med 2 (1987), 183–187.
100. Katapodi, MC, Dodd, MJ, Facione, NC, Humphreys, JC, Lee, KA, Why some women have an optimistic or a pessimistic bias about their breast cancer risk: experiences, heuristics, and knowledge of risk factors. Cancer Nurs 33 (2010), 64–73.
101. Dunn, AG, Arachi, D, Hudgins, J, Tsafnat, G, Coiera, E, Bourgeois, FT, Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Ann Intern Med 161 (2014), 513–518.
102. Wang, AT, McCoy, CP, Murad, MH, Montori, VM, Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ, 340, 2010, c1344.
103. Metlay, JP, Shea, JA, Crossette, LB, Asch, DA, Tensions in antibiotic prescribing. J Gen Intern Med 17 (2002), 87–94.
104. Isaacs, DM, Marinac, J, Sun, C, Radiograph use in low back pain: a United States Emergency Department database analysis. J Emerg Med 26 (2004), 37–45.
105. Sugarman, DB, Active versus passive euthanasia: An attributional analysis. J Appl Soc Psychol 16 (1986), 60–76.
106. Bunker, JP, Frazier, HS, Mosteller, F, Improving health: measuring effects of medical care. Milbank Q 72 (1994), 225–258.
107. Bunker, JP, Medicine matters after all. J R Coll Physicians Lond 29 (1995), 105–112.
108. Kondo, N, Socioeconomic disparities and health: impacts and pathways. J Epidemiol 22 (2012), 2–6.
109. Adler, NE, Newman, K, Socioeconomic disparities in health: pathways and policies. Health Aff 21 (2002), 60–76.
110. Braveman, PA, Cubbin, C, Egerter, S, Williams, DR, Pamuk, E, Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health 100:suppl 1 (2010), S186–S196.
111. Bunker, JP, The role of medical care in contributing to health improvements within societies. Int J Epidemiol 30 (2001), 1260–1263.
112. Commission on Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. http://apps.who.int/iris/bitstream/10665/43943/1/9789241563703_eng.pdf, 2008 (accessed Dec 8, 2016).
113. Roychowdhury, S, Chinnaiyan, AM, Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 31 (2013), 1866–1873.
114. National Research Council of the National Academies. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease, 2011, National Academies Press, Washington, DC.
115. Jolicoeur, EM, Granger, CB, Henry, TD, et al. Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies. Am Heart J 155 (2008), 418–434.
116. Konski, A, Speier, W, Hanlon, A, Beck, JR, Pollack, A, Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 25 (2007), 3603–3608.
117. Starr, P, The social transformation of American medicine, 1982, Basic Books Inc., Publishers, New York.
118. Carson, AJ, Ringbauer, B, Stone, J, McKenzie, L, Warlow, C, Sharpe, M, Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatient clinics. J Neurol Neurosurg Psychiatry 68 (2000), 207–210.
119. Weeks, JC, Catalano, PJ, Cronin, A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367 (2012), 1616–1625.
120. Cochrane, AL, Effectiveness and efficiency: random reflections on health services, 1973, Nuffield Provinicial Hospital Trust, London.
121. Chalmers, I, Glasziou, P, Avoidable waste in the production and reporting of research evidence. Lancet 374 (2009), 86–89.
122. Dartmouth Atlas of Health Care. End-of-life care in California: you don't always get what you want. http://www.chcf.org/Publications/2013/04/EOL-What-You-Want/, 2013 (accessed Dec 8, 2016).
123. Mulley, AG, Trimble, C, Elwyn, G, Stop the silent misdiagnosis: patients' preferences matter. BMJ, 345, 2012, e6572.
124. Hawker, GA, Wright, JG, Coyte, PC, et al. Determining the need for hip and knee arthroplasty: the role of clinical severity and patients' preferences. Med Care 39 (2001), 206–216.
125. Dartmouth Atlas Project and Lown Institute. Measuring Up? End-of-life cancer care in California. http://www.chcf.org/publications/2013/08/measuring-up-eol-cancer, 2013 (accessed Dec 1, 2016).
126. Abbott, AL, Adelman, MA, Alexandrov, AV, et al. Why calls for more routine carotid stenting are currently inappropriate: an international, multispecialty, expert review and position statement. Stroke 44 (2013), 1186–1190.
127. Chan, PS, Patel, MR, Klein, LW, et al. Appropriateness of percutaneous coronary intervention. JAMA 306 (2011), 53–61.
128. Røttingen, J-A, Regmi, S, Eide, M, et al. Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?. Lancet 382 (2013), 1286–1307.
129. Lathyris, D, Patsopoulos, N, Salanti, G, Ioannidis, J, Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest 40 (2010), 172–182.
130. Flacco, ME, Manzoli, L, Boccia, S, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 68 (2015), 811–820.
131. Rogers, EM, Diffusion of innovations, 2003, Simon & Schuster, Inc., New York.
132. Moynihan, R, Henry, D, Moons, KG, Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much. PLoS Med, 11, 2014, e1001655.
133. Elshaug, AG, Hiller, JE, Tunis, SR, Moss, JR, Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust New Zealand Health Policy, 4, 2007, 23.
134. Chalmers, I, Bracken, MB, Djulbegovic, B, et al. How to increase value and reduce waste when research priorities are set. Lancet 383 (2014), 156–165.
135. Prasad, V, Cifu, A, Medical reversal: why we must raise the bar before adopting new technologies. Yale J Biol Med 84 (2011), 471–478.
136. Institute of Medicine of the National Academies. Conflict of interest and medical innovation: ensuring integrity while facilitating innovation in medical research: workshop summary 2014, 2014, National Academies Press, Washington, DC.
137. Runciman, WB, Hunt, TD, Hannaford, NA, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. Med J Aust, 197, 2012, 549.
138. Lenzer, J, Hoffman, JR, Furberg, CD, Ioannidis, JP, Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ, 347, 2013.
139. Gøtzsche, PC, Ioannidis, JP, Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses?. BMJ, 345, 2012, e7031.
140. Steinberg, E, Greenfield, S, Mancher, M, Wolman, DM, Graham, R, Clinical practice guidelines we can trust, 2011, National Academies Press, Washington, DC.
141. Medolago, G, Marcassa, C, Alkraisheh, A, Campini, R, Ghilardi, A, Giubbini, R, Applicability of the appropriate use criteria for SPECT myocardial perfusion imaging in Italy: preliminary results. Eur J Nucl Med Mol Imaging 41 (2014), 1695–1700.
142. Charles, C, DeMaio, S, Lay participation in health care decision making: a conceptual framework. J Health Polit Policy Law 18 (1993), 881–904.
143. Joseph-Williams, N, Edwards, A, Elwyn, G, Power imbalance prevents shared decision making. BMJ, 348, 2014, g3178.
144. Légaré, F, Ratté, S, Gravel, K, Graham, ID, Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions. Patient Educ Couns 73 (2008), 526–535.
145. Falcone, D, Broyles, R, Access to long-term care: race as a barrier. J Health Polit Policy Law 19 (1994), 583–595.
146. Brilliant, GE, Lepkowski, JM, Zurita, B, Thulasiraj, R, Social determinants of cataract surgery utilization in south India. Arch Ophthalmol 109 (1991), 584–589.
147. Barros, AJ, Santos, IS, Matijasevich, A, et al. Patterns of deliveries in a Brazilian birth cohort: almost universal cesarean sections for the better-off. Rev Saude Publica 45 (2011), 635–643.
148. Belizan, JM, Althabe, F, Barros, FC, Alexander, S, Rates and implications of caesarean sections in Latin America: ecological study. BMJ 319 (1999), 1397–1400.
149. Chen, L, Primary health care in developing countries: overcoming operational, technical, and social barriers. Lancet 328 (1986), 1260–1265.
150. Lindert, J, Schouler-Ocak, M, Heinz, A, Priebe, S, Mental health, health care utilisation of migrants in Europe. Eur Psychiatry 23 (2008), 14–20.
151. Bäärnhielm, S, Saers, K, Mental illness among immigrants and refugees. Are needs and available care adequate?. Lakartidningen 95 (1998), 1532–1534 (in Swedish).
152. Feranil, AB, Anaemia among migrant and non-migrant mothers in disadvantaged areas in the Visayas, the Philippines. Jatrana, S, Toyota, M, Yeoh, B, (eds.) Migration and Health in Asia, 2005, Routledge, London, 100–115.
153. Street, RL, Makoul, G, Arora, NK, Epstein, RM, How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns 74 (2009), 295–301.
154. Bauer, AM, Parker, MM, Schillinger, D, et al. Associations between antidepressant adherence and shared decision-making, patient-provider trust, and communication among adults with diabetes: diabetes study of northern California (DISTANCE). J Gen Intern Med 29 (2014), 1139–1147.
155. Ratanawongsa, N, Karter, AJ, Parker, MM, et al. Communication and medication refill adherence: the Diabetes Study of Northern California. JAMA Intern Med 173 (2013), 210–218.
156. Karter, AJ, Parker, MM, Moffet, HH, Ahmed, AT, Schmittdiel, JA, Selby, JV, New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44 (2009), 1640–1661.
157. Patel, VL, Kaufman, DR, Arocha, JF, Emerging paradigms of cognition in medical decision-making. J Biomed Inform 35 (2002), 52–75.
158. Djulbegovic, B, Hozo, I, Ioannidis, J, Modern health care as a game theory problem: reply. Eur J Clin Invest, 45, 2015, 443.
159. Lehman, R, Tejani, AM, McCormack, J, Perry, T, Yudkin, JS, Ten commandments for patient-centred treatment. Br J Gen Pract 65 (2015), 532–533.
160. Floer, B, Schnee, M, Bocken, J, et al. Shared decision making. The perspective of practicing physicians. Med Klin (Munich) 99 (2004), 435–440 (in German).
161. Morrow, G GJ, Schmale, A, A simple technique for increasing cancer patients' knowledge of informed consent to treatment. Cancer 42 (1978), 793–799.
162. King, JS, Moulton, BW, Rethinking informed consent: the case for shared medical decision-making. Am J Law Med 32 (2006), 429–501.
163. Arnold, SV, Decker, C, Ahmad, H, et al. Converting the informed consent from a perfunctory process to an evidence-based foundation for patient decision making. Circ Cardiovasc Qual Outcomes 1 (2008), 21–28.
164. Elwyn, G, Frosch, D, Thomson, R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med 27 (2012), 1361–1367.
165. Légaré, F, Labrecque, M, Cauchon, M, Castel, J, Turcotte, S, Grimshaw, J, Training family physicians in shared decision-making to reduce the overuse of antibiotics in acute respiratory infections: a cluster randomized trial. Can Med Assoc J 184 (2012), E726–E734.
166. O'Connor, AM, Llewellyn-Thomas, HA, Flood, AB, Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood)(Suppl Variation), 2004, VAR63–VAR72.
167. Kennedy, AD, Sculpher, MJ, Coulter, A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 288 (2002), 2701–2708.
168. Stacey, D, Légaré, F, Col, NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev, 1, 2014 CD001431.
169. Gafni, A, Birch, S, Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 62 (2006), 2091–2100.
170. Nelkin, D, An uneasy relationship: the tensions between medicine and the media. Lancet 347 (1996), 1600–1603.
171. Towle, A, Godolphin, W, Framework for teaching and learning informed shared decision making. BMJ, 319, 1999, 766.
172. Carpenter, D, Moss, DA, Preventing regulatory capture: special interest influence and how to limit it, 2013, Cambridge University Press, New York.
173. Brinkerhoff, DW, Bossert, TJ, Health governance: principal–agent linkages and health system strengthening. Health Policy Plan 29 (2014), 685–693.
174. Wolfe, S, Worth, M, Dreyfus, S, Brown, A, Whistleblower protection rules in G20 countries: the next action plan. http://transparency.org.au/wp-content/uploads/2014/06/Action-Plan-June-2014-Whistleblower-Protection-Rules-G20-Countries.pdf, 2014 (accessed Dec 1, 2016).
175. EMA's revolving door with Big Pharma—alive and well. https://corporateeurope.org/revolving-doors/2014/06/emas-revolving-door-big-pharma-alive-and-well, 2014 (accessed Dec 1, 2016).
176. Raphael, D, Curry-Stevens, A, Bryant, T, Barriers to addressing the social determinants of health: insights from the Canadian experience. Health Policy 88 (2008), 222–235.
177. Raphael, D, Bryant, T, The state's role in promoting population health: Public health concerns in Canada, USA, UK, and Sweden. Health Policy 78 (2006), 39–55.
178. Grilli, R, Ramsay, C, Minozzi, S, Mass media interventions: effects on health services utilisation. Cochrane Database Syst Rev, 2002 CD00389.
179. Wakefield, MA, Loken, B, Hornik, RC, Use of mass media campaigns to change health behaviour. Lancet 376 (2010), 1261–1271.
180. Walsh-Childers, K, Braddock, J, Competing with the conventional wisdom: newspaper framing of medical overtreatment. Health Commun 29 (2014), 157–172.
181. Jacobson, PD, Brownlee, S, The health insurance industry and the media: why the insurers aren't always wrong. Houston J Health Law Policy 5 (2005), 235–267.
182. Rahbari, M, Rahbari, NN, Compassionate use of medicinal products in Europe: current status and perspectives. Bull World Health Organ, 89, 2011, 163.
183. Howard, DH, Drug companies' patient-assistance programs—helping patients or profits?. N Engl J Med 371 (2014), 97–99.
184. Moynihan, R, Key opinion leaders: independent experts or drug representatives in disguise?. BMJ 336 (2008), 1402–1403.
185. Moynihan, RN, Cooke, GP, Doust, JA, Bero, L, Hill, S, Glasziou, PP, Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med, 10, 2013, e1001500.
186. Moynihan, R, Heath, I, Henry, D, Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324 (2002), 886–891.
187. Abramson, J, Overdosed America: The broken promise of American medicine: how pharmaceutical companies distort medical knowledge, mislead doctors, and compromise your health, 2004, Harper Collins, New York.
188. Welch, HG, Schwartz, L, Woloshin, S, Overdiagnosed: making people sick in the pursuit of health, 2011, Beacon Press, Boston.
189. Cosgrove, L, Krimsky, S, A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists. PLoS Med, 9, 2012, e1001190.
190. Frosch, DL, Krueger, PM, Hornik, RC, Cronholm, PF, Barg, FK, Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med 5 (2007), 6–13.
191. Donohue, JM, Cevasco, M, Rosenthal, MB, A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 357 (2007), 673–681.
192. Moynihan, R, Drug maker's PR firm is force behind blood clot awareness campaign. BMJ, 336, 2008, 1460.
193. Ingelheim, B, Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects. http://www.europeanpharmaceuticalreview.com/13078/news/industry-news/boehringer-ingelheim-launches-firstofakind-fundraising-model-support-disease-awareness-projects/, 2012 (accessed Dec 1, 2016).
194. Herxheimer, A, Relationships between the pharmaceutical industry and patients' organisations. BMJ, 326, 2003, 1208.
195. Mintzes, B, Should patient groups accept money from drug companies? No. BMJ, 334, 2007, 935.
196. Koerner, BI, Disorders made to order. Mother Jones 27 (2002), 58–81.
197. Woloshin, S, Schwartz, LM, Giving legs to restless legs: a case study of how the media helps make people sick. PLoS Med, 3, 2006, 452.
198. Tiefer, L, Female sexual dysfunction: a case study of disease mongering and activist resistance. PLoS Med, 3, 2006, 436.
199. Moynihan, R, Cassels, A, Selling sickness, 2005, Nation Books, New York.
200. Rothman, DJ, McDonald, WJ, Berkowitz, CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 301 (2009), 1367–1372.
201. Kassirer, JP, Professional societies and industry support: what is the quid pro quo?. Perspect Biol Med 50 (2007), 7–17.
202. Debré, B, Rapport sur le dépistage du cancer de la prostate. http://www.assemblee-nationale.fr/14/rap-info/i1582.asp, 2009 (accessed Dec 1, 2016).
203. Steinbrook, R, Financial support of continuing medical education. JAMA 299 (2008), 1060–1062.
204. Thompson, DF, Understanding financial conflicts of interest. N Engl J Med 329 (1993), 573–576.
205. Lieb, K, Scheurich, A, Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One, 9, 2014, e110130.
206. Dave, DM, Effects of pharmaceutical promotion: a review and assessment. NBER Work Pap Ser, 2013.
207. Warrier, R, Monaghan, M, Maio, A, Huggett, K, Rich, E, Effect of drug sample availability on physician prescribing behavior: a systematic review. Clin Rev Opin 2 (2010), 41–48.
208. Anderson, R, Pharmaceutical industry gets high on fat profit. BBC News, 6, Nov 6, 2014.
209. Barnett, ML, Linder, JA, Antibiotic prescribing for adults with acute bronchitis in the United States, 1996–2010. JAMA 311 (2014), 2020–2022.
210. Carrier, ER, Reschovsky, JD, Katz, DA, Mello, MM, High physician concern about malpractice risk predicts more aggressive diagnostic testing in office-based practice. Health Aff (Millwood) 32 (2013), 1383–1391.
211. Avraham, R, Dafny, LS, Schanzenbach, MM, The impact of tort reform on employer-sponsored health insurance premiums. J Law Econ Organ 28 (2012), 657–686.
212. Mello, MM, Chandra, A, Gawande, AA, Studdert, DM, National costs of the medical liability system. Health Aff 29 (2010), 1569–1577.
213. Beider, P, Hagen, SA, Limiting tort liability for medical malpractice. http://www.policyalmanac.org/health/archive/medical_malpractice_cbo.shtml, 2004 (accessed Dec 1, 2016).
214. Wennberg, JE, Tracking medicine: a researcher's quest to understand health care, 2010, Oxford University Press, New York.